# PinotBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pinotbio

- Industry: Biotechnology
- Headquarters: Suwon, South Korea
- Website: www.pinotbio.com/
- Total disclosed funding: $21M
- Latest round: Series B (Dec 19, 2019)
- Investors on record: 10

## About

Founded in 2017 and based in Suwon, South Korea, PinotBio operates as a biotechnology company that develops and manufactures anticancer drugs. In October 2025, PinotBio raised KRW 13 billion in pre-IPO funding from new investor Mirae Asset Capital, with participation from returning investors KB Investment, Union Investment Partners, BNH Investment, and Mirae Asset Venture Investment. The company will use the October 2025 funding to further advance its antibody-drug conjugate pipeline and pursue initial public offering.

## Funding rounds

- Series B, Dec 19, 2019, $8.6M — Shinhan Financial Group, KB Investment, Partners Investment, Devsisters Ventures, STIC Ventures, Idea Bridge Asset Management, Stonebridge Ventures
- Series A, Dec 1, 2018, $9.7M — E&Investment, Partners Investment, Mirae Asset Venture Investment
- Seed, Nov 25, 2017, $2.7M — Company K Partners, Mirae Asset Venture Investment

## Investors

- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Seed
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Seed, Series A
- E&Investment (https://capitalatlas.ai/funds/e-investment) — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A, Series B
- Shinhan Financial Group — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Devsisters Ventures (https://capitalatlas.ai/funds/devsisters-ventures) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- Idea Bridge Asset Management — Series B
- Stonebridge Ventures — Series B